SOLiD vs Illumina

SOLiD and Illumina are two major players in the genomics industry, specializing in DNA sequencing technologies. Both companies have seen fluctuating stock prices in recent years as the demand for genetic testing and personalized medicine continues to grow. SOLiD, a subsidiary of Thermo Fisher Scientific, has faced challenges in maintaining market share against competitors like Illumina. Meanwhile, Illumina has established itself as a leader in the industry, offering innovative sequencing platforms and services. Investors interested in genomics stocks should closely monitor the performance of both SOLiD and Illumina to make informed investment decisions.

SOLiD or Illumina?

When comparing SOLiD and Illumina, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between SOLiD and Illumina.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. SOLiD has a dividend yield of 1.1%, while Illumina has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. SOLiD reports a 5-year dividend growth of 0.00% year and a payout ratio of 6.19%. On the other hand, Illumina reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with SOLiD P/E ratio at 5.64 and Illumina's P/E ratio at -7.71. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. SOLiD P/B ratio is 0.93 while Illumina's P/B ratio is 16.34.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, SOLiD has seen a 5-year revenue growth of 0.13%, while Illumina's is 0.26%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with SOLiD's ROE at 17.74% and Illumina's ROE at -64.72%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are ₩4475.00 for SOLiD and $145.58 for Illumina. Over the past year, SOLiD's prices ranged from ₩4035.00 to ₩7370.00, with a yearly change of 82.65%. Illumina's prices fluctuated between $86.58 and $151.37, with a yearly change of 74.84%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.